BridgeMD
STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR
EU CTIS ID: 2024-511001-28-00
What this study is testing
To evaluate the efficacy of two additional cycles of Lutathera® (one injection every two months), compared to active surveillance during 6 months in patients already retreated with two cycles.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years
- Measurable disease per RECIST 1.1 (Appendix 1), on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumors lesions in total
- Adequate bone marrow reserve (Hb > 8 g/dl, neutrophils ≥ 1500/mm³ and platelets ≥ 80 000/mm³),
- Negative pregnancy test in women of childbearing potential (the β-HCG dosage must be ≤ 4 days before inclusion). Women who have no reproductive potential are postmenopausal women or women who have had permanent sterilization, eg. tubal occlusion, hysterectomy, bilateral salpingectomy),
- Effective contraception in men or women of childbearing or pre-menopausal age and up to a minimum of 7 months for female patients and 4 months for male patients following the end of treatment,
- Patient´s signed written informed consent
You likely can't join if
- Patient who did not respond (no CR, PR or SD) to “first PRRT”.
- Uncontrolled decompensated heart failure, myocardial infarction uncontrolled, stroke, pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months,
- Hypertension that cannot be controlled despite medications (≥ 160/95 mmHg despite optimal medical therapy)
- Brain metastases (unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrolment in the study. Patients with a history of brain metastases must have a head CT scan with contrast or MRI to document stable disease prior to enrolment in the study),
- Pregnancy or breast feeding
- Substance abuse, medical, psychological, or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results,
See the full eligibility criteria
Who can join
- Age ≥ 18 years
- Measurable disease per RECIST 1.1 (Appendix 1), on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumors lesions in total
- Adequate bone marrow reserve (Hb > 8 g/dl, neutrophils ≥ 1500/mm³ and platelets ≥ 80 000/mm³),
- Negative pregnancy test in women of childbearing potential (the β-HCG dosage must be ≤ 4 days before inclusion). Women who have no reproductive potential are postmenopausal women or women who have had permanent sterilization, eg. tubal occlusion, hysterectomy, bilateral salpingectomy),
- Effective contraception in men or women of childbearing or pre-menopausal age and up to a minimum of 7 months for female patients and 4 months for male patients following the end of treatment,
- Patient´s signed written informed consent
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
- Affiliation to the French Social Security System.
- Histologically proven intestinal G1 or G2 neuroendocrine tumors (NET),
- Patient previously treated with 4 cycles of Lutathera® (defined as “First PRRT”),
- Disease control after “First PRRT” ≥ 12 months
- Patient presenting a progression of disease (clinic, biologic and/or radiologic) after a first PRRT
- Decision of retreatment with Lutathera® (defined as “Second PRRT”) validated by RENATEN and/or multidisciplinary tumor board and in the scope of the French reimbursement process
- ECOG performance status 0-2
- Life expectancy ≥ 6 months as prognosticated by the physician
- Somatostatin receptor imaging positive imaging (SSTRi+) disease within 4 months prior to inclusion: (may be PET imaging (68Ga-based SSTR analogues) or scintigraphy imaging: 111In-pentetreotide or 99mTc-octreotide. At least 90% of lesions must be positive for SSTRi with a significant uptake (>= liver or surrounding tissue),
What rules you out
- Patient who did not respond (no CR, PR or SD) to “first PRRT”.
- Uncontrolled decompensated heart failure, myocardial infarction uncontrolled, stroke, pulmonary embolism or revascularization procedure, unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months,
- Hypertension that cannot be controlled despite medications (≥ 160/95 mmHg despite optimal medical therapy)
- Brain metastases (unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrolment in the study. Patients with a history of brain metastases must have a head CT scan with contrast or MRI to document stable disease prior to enrolment in the study),
- Pregnancy or breast feeding
- Substance abuse, medical, psychological, or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results,
- Known hypersensitivity to any of the study drugs, study drug classes, or any constituent of the products,
- Concomitant participation or participation within the last 30 days in another clinical trial,
- History of other solid tumor in 5 years before the inclusion excepted of cancer in situ of the cervix and skin cancer (basal or squamous cell) treated and controlled.
- Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.
- Radiological progression after two cycles of “Second PRRT” according to RECIST version 1.1
- Grade 4 hematotoxicity and/or nephrotoxicity during the initial PRRT, or unresolved AEs categorized as Grade 2 or higher (as per Common Terminology Criteria for Adverse Events (CTCAE v5.0) from previous PRRT cycles or any other therapy for NET, excluding alopecia and peripheral neuropathy,
- Pancreatic NET,
- NeuroEndocrine Carcinoma,
- Prior external beam radiation therapy to more than 25% of the bone marrow,
- Severe renal (estimated Glomerular Filtration Rate (GFR) according to Cockcroft Gault method < 40 mL/min or nephrotic syndrome) or hepatic insufficiency (Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) > 2.5 x ULN or ALT/AST > 5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN),
- Serum albumin < 3.0 g/dL unless prothrombin time is within the normal range,
- Uncontrolled diabetes mellitus as defined by a fasting blood glucose above 2 ULN,
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.